Nomogram to predict primary non-response to infliximab in patients with Crohn’s disease: a multicenter study

BACKGROUND: Infliximab (IFX) is effective at inducing and maintaining clinical remission and mucosal healing in patients with Crohn’s disease (CD); however, 9%–40% of patients do not respond to primary IFX treatment. This study aimed to construct and validate nomograms to predict IFX response in CD...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Xiao-Qi, Cai, Jing, Yu, Qiao, Cao, Xiao-Cang, Chen, Yan, Rao, Mei-Xin, Chen, Bai-Li, He, Yao, Zeng, Zhi-Rong, Chen, Hao, Lin, Yi-Mou, Cao, Qian, Chen, Min-Hu, Zhang, Sheng-Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460115/
https://www.ncbi.nlm.nih.gov/pubmed/34567565
http://dx.doi.org/10.1093/gastro/goaa069

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460115/
https://www.ncbi.nlm.nih.gov/pubmed/34567565
http://dx.doi.org/10.1093/gastro/goaa069

Ejemplares similares